Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ocrelizumab

ocrelizumab

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ocrelizumab

14 trials tracked of ocrelizumab: 11 in phase 3 or 4 and 6 with published results. The most-cited published study has 62 citations.

14Trials tracked
11Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 4 Phase 3 7 Phase 2 1 Other / NA 2
  1. Phase 3 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Completed · 62 cited
  2. Phase 3 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Completed · 29 cited
  3. Phase 3 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Completed · 12 cited
  4. Phase 3 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Completed · 12 cited
  5. Phase 4 Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis Completed · 1 cited
  6. Phase 4 Short-term B-cell Depletion in Relapsing Multiple Sclerosis Completed · 1 cited
Show 8 more trials
  1. Phase 4 A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab Completed
  2. Phase 4 A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy Completed
  3. Phase 3 Safety of Switching From Rituximab to Ocrelizumab in MS Patients Completed
  4. Phase 3 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Completed
  5. Phase 3 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Completed
  6. Phase 2 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis Completed
  7. N/A Mechanism of Action of Ocrelizumab in Multiple Sclerosis Completed
  8. N/A Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS
Neurology RCT
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS High-dose ocrelizumab did not further reduce disability progression in multiple sclerosis patients
This phase 3b randomized controlled trial in 860 and 753 patients with relapsing or primary progressive multiple sclerosis found that high-d…
A large trial found that higher doses of ocrelizumab did not lower the risk of disability progression compared to the standard dose in multi…
May 30, 2026
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
Neurology RCT
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
This phase 3b trial evaluated intravenous ocrelizumab versus placebo in patients with primary progressive multiple sclerosis. The study foun…
A large trial found ocrelizumab significantly lowers the risk of disability progression in patients with primary progressive multiple sclero…
May 30, 2026
Marburg MS case shows treatment challenges and fatal outcome
Dermatology Sys. Review
Marburg MS case shows treatment challenges and fatal outcome A Rare MS Variant Defied Treatment Until This Switch
A 46-year-old woman with aggressive Marburg MS faced treatment-limiting toxicity and died despite multiple therapies, highlighting urgent ca…
A woman with a rare, aggressive form of multiple sclerosis tried many treatments without success, and doctors tried a new approach too late.
Frontiers May 15, 2026
Ocrelizumab treatment in multiple sclerosis shows disability improvement in relapsing forms
Neurology Phase III
Ocrelizumab treatment in multiple sclerosis shows disability improvement in relapsing forms MS Drugs Stop Relapses But Miss This Silent Disability Threat
This retrospective longitudinal cohort study analyzed 1859 people with multiple sclerosis treated with ocrelizumab. Disability improvement w…
• Top MS drugs fix sudden relapses but not slow nerve damage • Helps people with all MS types facing hidden progression • Not a new treatmen…
medRxiv May 10, 2026
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt
Neurology RCT
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt High-dose melatonin trial halted after liver safety concerns in MS patients
A phase I/II RCT of 8 patients with PP-MS on stable ocrelizumab found that adjunctive high-dose oral melatonin (300 mg/day) was associated w…
A high-dose melatonin trial for multiple sclerosis stopped early after three of four patients developed mild liver injury, though the issue …
Apr 4, 2026